Download Physiologically Based Pharmacokinetic (PBPK) Modeling Ebook PDF

Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations

Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations
Principles, Methods, and Applications in the Pharmaceutical Industry

by Sheila Annie Peters

  • Publisher : John Wiley & Sons
  • Release : 2012-02-17
  • Pages : 450
  • ISBN : 1118140303
  • Language : En, Es, Fr & De
GET BOOK

The only book dedicated to physiologically-based pharmacokineticmodeling in pharmaceutical science Physiologically-based pharmacokinetic (PBPK) modeling has becomeincreasingly widespread within the pharmaceutical industry over thelast decade, but without one dedicated book that provides theinformation researchers need to learn these new techniques, itsapplications are severely limited. Describing the principles,methods, and applications of PBPK modeling as used inpharmaceutics, Physiologically-Based Pharmacokinetic (PBPK)Modeling and Simulations fills this void. Connecting theory with practice, the book explores theincredible potential of PBPK modeling for improving drug discoveryand development. Comprised of two parts, the book first provides adetailed and systematic treatment of the principles behindphysiological modeling of pharmacokinetic processes,inter-individual variability, and drug interactions for smallmolecule drugs and biologics. The second part looks in greaterdetail at the powerful applications of PBPK to drug research. Designed for a wide audience encompassing readers looking for abrief overview of the field as well as those who need more detail,the book includes a range of important learning aids. Featuringend-of-chapter keywords for easy reference—a valuable assetfor general or novice readers without a PBPK background—alongwith an extensive bibliography for those looking for furtherinformation, Physiologically- Based Pharmacokinetic (PBPK) Modelingand Simulations is the essential single-volume text on one of thehottest topics in the pharmaceutical sciences today.

Physiologically Based Pharmacokinetic (PBPK) Modeling

Physiologically Based Pharmacokinetic (PBPK) Modeling
Methods and Applications in Toxicology and Risk Assessment

by Jeffrey W. Fisher,Jeffery M. Gearhart,Zhoumeng Lin

  • Publisher : Academic Press
  • Release : 2020-05-20
  • Pages : 346
  • ISBN : 0128196823
  • Language : En, Es, Fr & De
GET BOOK

Physiologically Based Pharmacokinetic (PBPK) Modeling: Methods and Applications in Toxicology and Risk Assessment presents foundational principles, advanced techniques and applications of PBPK modeling. Contributions from experts in PBPK modeling cover topics such as pharmacokinetic principles, classical physiological models, the application of physiological models for dose-response and risk assessment, the use of in vitro information, and in silico methods. With end-of-chapter exercises that allow readers to practice and learn the skills associated with PBPK modeling, dose-response, and its applications to safety and risk assessments, this book is a foundational resource that provides practical coverage of PBPK modeling for graduate students, academics, researchers, and more. Provides end-of-chapter exercises to teach hands-on computational tools used in toxicology Supplies computer code and explanations and includes examples of applied models used in regulatory toxicology and research Authored by expert editors and contributors who are among the best PBPK modelers in the world

Physiologically Based Pharmacokinetic Modeling

Physiologically Based Pharmacokinetic Modeling
Science and Applications

by Micaela Reddy,R. S. Yang,Melvin E. Andersen,Harvey J. Clewell III

  • Publisher : John Wiley & Sons
  • Release : 2005-06-14
  • Pages : 420
  • ISBN : 0471478776
  • Language : En, Es, Fr & De
GET BOOK

A definitive, single source of information on PBPK modeling Physiologically-based pharmacokinetic (PBPK) modeling is becomingincreasingly important in human health risk assessments and insupporting pharmacodynamic modeling for toxic responses. Organizedby classes of compounds and modeling purposes so users can quicklyaccess information, this is the first comprehensive reference ofits kind. This book presents an overview of the underlying principles of PBPKmodel development. Then it provides a compendium of PBPK modelinginformation, including historical development, specific modelingchallenges, and current practices for: * Halogenated Alkanes * Halogenated Alkenes * Alkene and Aromatic Compounds * Reactive Vapors in the Nasal Cavity * Alkanes, Oxyhydrocarbons, and Related Compounds * Pesticides and Persistent Organic Pollutants * Dioxin and Related Compounds * Metals and Inorganic Compounds * Drugs * Antineoplastic Agents * Perinatal Transfer * Mixtures * Dermal Exposure Models In addition to pinpointing specific information, readers canexplore diverse modeling techniques and applications. Anauthoritative reference for toxicologists, ecotoxicologists, riskassessors, regulators, pharmacologists, pharmacists, and graduatestudents in pharmacokinetics and toxicology, Physiologically-BasedPharmacokinetic Modeling compiles information from leaders in thefield and discusses future directions for PBPK modeling.

Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, Third Edition

Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, Third Edition
A Book

by Johan Gabrielsson,Daniel Weiner

  • Publisher : CRC Press
  • Release : 2001-11-30
  • Pages : 924
  • ISBN : 9789186274924
  • Language : En, Es, Fr & De
GET BOOK

This is a revised and very expanded version of the previous second edition of the book. "Pharmacokinetic and Pharmacodynamic Data Analysis" provides an introduction into pharmacokinetic and pharmacodynamic concepts using simple illustrations and reasoning. It describes ways in which pharmacodynamic and pharmacodynamic theory may be used to give insight into modeling questions and how these questions can in turn lead to new knowledge. This book differentiates itself from other texts in this area in that it bridges the gap between relevant theory and the actual application of the theory to real life situations. The book is divided into two parts; the first introduces fundamental principles of PK and PD concepts, and principles of mathematical modeling, while the second provides case studies obtained from drug industry and academia. Topics included in the first part include a discussion of the statistical principles of model fitting, including how to assess the adequacy of the fit of a model, as well as strategies for selection of time points to be included in the design of a study. The first part also introduces basic pharmacokinetic and pharmacodynamic concepts, including an excellent discussion of effect compartment (link) models as well as indirect response models. The second part of the text includes over 70 modeling case studies. These include a discussion of the selection of the model, derivation of initial parameter estimates and interpretation of the corresponding output. Finally, the authors discuss a number of pharmacodynamic modeling situations including receptor binding models, synergy, and tolerance models (feedback and precursor models). This book will be of interest to researchers, to graduate students and advanced undergraduate students in the PK/PD area who wish to learn how to analyze biological data and build models and to become familiar with new areas of application. In addition, the text will be of interest to toxicologists interested in learning about determinants of exposure and performing toxicokinetic modeling. The inclusion of the numerous exercises and models makes it an excellent primary or adjutant text for traditional PK courses taught in pharmacy and medical schools. A diskette is included with the text that includes all of the exercises and solutions using WinNonlin.

Toxicokinetics and Risk Assessment

Toxicokinetics and Risk Assessment
A Book

by John C. Lipscomb,Edward V. Ohanian

  • Publisher : CRC Press
  • Release : 2016-04-19
  • Pages : 361
  • ISBN : 1000612139
  • Language : En, Es, Fr & De
GET BOOK

Toxicokinetics in Risk Assessment discusses the noncancer risk assessment process and its reliance on uncertainty factors in order to facilitate the continued study and refinement of the scientific basis for health risk assessment. This text clearly demonstrates the application of physiologically-based pharmacokinetic (PBPK) modeling in human healt

New Technologies for Toxicity Testing

New Technologies for Toxicity Testing
A Book

by Michael Balls,Robert D. Combes,Nirmala Bhogal

  • Publisher : Springer Science & Business Media
  • Release : 2012-03-22
  • Pages : 258
  • ISBN : 1461430550
  • Language : En, Es, Fr & De
GET BOOK

The central theme running through this volume on New Technologies for Toxicity Testing is the development and application of advanced techniques for cell and tissue culture, as well as new markers and endpoints of toxicity, as alternatives to the traditional paradigm of relying on data from laboratory animal tests to undertake labelling and risk assessment. Of course, many of the techniques and methods described in this volume are in the early stages of development, and much work will be needed to ensure their further improvement, optimisation and validation. However, we are confident that this will be achieved and that, just as with the in vitro assays that were validated and granted regulatory acceptance over the last decade, these, and many other new, advanced methods, will likewise become part of the toxicologist’s improved toolbox for coping with increasingly stringent and numerous regulatory requirements and test chemicals, while placing less reliance on traditional testing paradigms.

Fundamentals of Pediatric Drug Dosing

Fundamentals of Pediatric Drug Dosing
A Book

by Iftekhar Mahmood,Gilbert Burckart

  • Publisher : Springer
  • Release : 2016-10-28
  • Pages : 146
  • ISBN : 3319437542
  • Language : En, Es, Fr & De
GET BOOK

Focused on pediatric physiology, pharmacology, pharmacokinetics and pharmacodynamics, this book illustrates the differences between the pediatric population and adults; knowledge of extreme importance not only during pediatric drug development but also in the clinical practice. Physicians, nurses, clinical pharmacologists, researchers and healthcare professionals will find this an invaluable resource. With the advent of pediatric exclusivity, and requirements to conduct clinical studies in children, an emphasis has been placed on finding a safe and efficacious dose of a drug in children. Children are not ‘small adults’, and drug dosing in this population requires special consideration. There are subtle physiological and biochemical differences among neonates, infants, children, adolescents and adults and dosing in pediatrics requires proper understanding of these factors. Furthermore, dosing in children, as in adults, should be based on pharmacokinetic and pharmacodynamic data. This is an evolving area, as pediatric pharmacokinetic studies are becoming mandatory for getting approval of new drugs in this population.

Mechanistic Physiologically Based Pharmacokinetic (PBPK) Modeling of Renal and Systemic Disposition of Drugs and Metabolites

Mechanistic Physiologically Based Pharmacokinetic (PBPK) Modeling of Renal and Systemic Disposition of Drugs and Metabolites
A Book

by Weize Huang

  • Publisher : Unknown Publisher
  • Release : 2020
  • Pages : 263
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Physiologically-based pharmacokinetic (PBPK) models integrate system specific anatomy and physiology information with drug specific physicochemical and pharmacokinetic properties to predict drug disposition. Such integration permits items, events, processes, and pathways to communicate and influence each other interactively. By taking advantage of such mechanistic nature of PBPK modeling, drug dispositions under untested scenarios could be predicted by extrapolation from observed data in known conditions. Renal clearance is one of the major pathways governing drug dispositions, which has three main mechanisms: unbound filtration, passive reabsorption, and active secretion. In comparison to intestinal absorption and hepatic metabolism, renal clearance has been relatively underappreciated. Controlled clinical experiments that test renal clearance changes under altered conditions and mechanisms have been primarily focusing on drug-drug interaction on active secretion. However, huge gaps in understanding renal clearance still exist in other areas such as altered urine pH and impaired renal function. Further, passive reabsorption has not been paid significant attention by the pharmaceutical field. Therefore, the overarching goal of this thesis is to leverage mechanistic PBPK modeling technique to understand and predict renal clearance of drugs and metabolites under altered urine pH and impaired renal function, with a special focus on compounds undergoing significant renal passive reabsorption. In Chapter 2, to predict the spatiodynamic process of renal passive reabsorption in human, we developed a dynamic physiologically-based mechanistic kidney model based on human data that can integrate drug permeability, tubular surface area, ionization status, and drug concentration gradient between lumen and system to estimate renal passive reabsorption and predict renal clearance of drugs. Using 46 test compounds with a variety of physicochemical properties, the model successfully predicted the renal clearances of 87% compounds within 2-fold and 98% compounds within 3-fold. Further, by incorporating active secretion, the model also successfully predicted the renal clearances of para-aminohippuric acid (PAH), cimetidine, salicylic acid, and memantine. In Chapter 3, to ensure the simulation output from PBPK models can be meaningfully compared to the arm vein plasma drug concentrations collected in clinical studies, we developed a forearm model that captures the tissue distribution at the peripheral sampling site using human arm physiology data, allowing for a better prediction of plasma drug concentrations that are comparable to observed data. The model was successfully verified using arterial and venous concentrations of nicotine, ketamine, lidocaine, and fentanyl simultaneously. Further, I demonstrated that use of a discrepant sampling site in PBPK modeling than observed clinical studies may lead to biased model evaluation, erroneous model parameterization, and misleading prediction in unstudied clinical scenarios. In Chapter 4, to predict the altered renal excretion and systemic AUC of drug and metabolite when urine pH is changed, the mechanistic kidney model developed and verified from Chapter 2 was integrated with the peripheral arm sampling and full body PBPK model developed from Chapter 3. The model was successfully verified with methamphetamine and amphetamine under varying urine pH statuses, and showed feasibility to predict quantitatively and clinically significant changes in drug and metabolite disposition under comedications and diseases that can alter urine pH. In Chapter 5, to predict renal clearance in patients with impaired renal function such as chronic kidney diseases, physiological changes in tubular flow and urine flow observed in chronic kidney disease patients were incorporated into the mechanistic kidney model developed and verified from Chapter 2. The model accounts for the adaptive renal tubular filtrate flows that decrease disproportionately with glomerular filtration rate, and was successfully verified using three parent-metabolite pairs, six non-permeable drugs, six permeable drugs, and two secreted drugs. In conclusion, in this thesis, I developed and verified a physiologically-based mechanistic kidney model to translate drug properties such as plasma protein binding, transcellular permeability, and active transport into renal clearance of drugs and metabolites. This mechanistic kidney model allows prediction of alterations in renal clearance of drugs and metabolites upon changes in urine pH and renal functions, and can be incorporated into a full-body PBPK model to predict alterations in systemic disposition of drugs and metabolites.

Nicotine and Related Alkaloids

Nicotine and Related Alkaloids
Absorption, distribution, metabolism and excretion

by J.W. Gorrod,J. Wahren

  • Publisher : Springer Science & Business Media
  • Release : 2012-12-06
  • Pages : 299
  • ISBN : 9401121109
  • Language : En, Es, Fr & De
GET BOOK

Nicotine is an alkaloid which is present, together with a number of minor alkaloids, in tobacco and a wide variety of other plants. The introduction of tobacco as a therapeutic agent against diverse pathologi cal and physiological conditions resulted in the widespread exposure of people to nicotine, and the subsequent recognition of the pleasurable effects of tobacco consumption. Tobacco may be used for pleasure by smoking it in pipes, cigars or cigarettes or by taking it in unsmoked form as oral and nasal tobacco snuff. Nonsmokers are exposed to nico tine through plant material and side-stream tobacco smoke. This means that in humans nicotine is always utilized in the presence of a very large variety of natural compounds or their pyrolysis products, depend ing on the route of administration. These compounds may modify the absorption, distribution, metabolism and excretion of nicotine and hence alter the duration of its pharmacological action. In recent years the use of nicotine in chewing gum and cutaneous patches has been developed as an aid to smoking cessation. The toxic properties of nicotine make it useful as an insecticide, which has led to its use in agriculture and horticulture. It has also recently been recog nized that tobacco consumption may be beneficial in the prevention of Parkinson's disease or in alleviating inflammatory bowel syndrome. The above observations have continued to stimulate research into the mode of action of this relatively simple molecule.

Ecotoxicology Modeling

Ecotoxicology Modeling
A Book

by James Devillers

  • Publisher : Springer Science & Business Media
  • Release : 2009-08-07
  • Pages : 412
  • ISBN : 9781441901972
  • Language : En, Es, Fr & De
GET BOOK

Ecotoxicology Modeling is a comprehensive and well-documented text providing a collection of computational methods to the ecotoxicologists primarily interested in the study of the adverse effects of chemicals, their mechanisms of action and/or their environmental fate and behavior. Avoiding mathematical jargon, the book presents numerous case studies to enable the reader to understand the interest but also the limitations of linear and nonlinear models in ecotoxicology. Written by an international team of scientists, Ecotoxicology Modeling is of primary interest to those whose research or professional activity is directly concerned with the development and application of models in ecotoxicology. It is also intended to provide the graduate and post-graduate students with a clear and accessible text covering the main types of modeling approaches used in environmental sciences.

Metabolite Safety in Drug Development

Metabolite Safety in Drug Development
A Book

by Suzanne L. Iverson

  • Publisher : John Wiley & Sons
  • Release : 2016-08-01
  • Pages : 352
  • ISBN : 111894965X
  • Language : En, Es, Fr & De
GET BOOK

A reference on drug metabolism and metabolite safety in the development phase, this book reviews the analytical techniques and experimental designs critical for metabolite studies. It features case studies of lessons learned and real world examples, along with regulatory perspectives from the US FDA and EMA. • Reviews the analytical techniques and experimental designs critical for metabolite studies • Covers methods including chirality, species differences, mass spectrometry, radiolabels, and in vitro / in vivo correlation • Discusses target pharmacology, in vitro systems aligned to toxicity tests, and drug-drug interactions • Includes perspectives from authors with firsthand involvement in industry and the study of drug metabolites, including viewpoints that have influenced regulatory guidelines

Quantitative Modeling in Toxicology

Quantitative Modeling in Toxicology
A Book

by Kannan Krishnan,Melvin E. Andersen

  • Publisher : John Wiley & Sons
  • Release : 2010-04-01
  • Pages : 504
  • ISBN : 0470686707
  • Language : En, Es, Fr & De
GET BOOK

Governments around the world are passing laws requiring industry to assess the toxicity of the chemicals and products they produce, but to do so while reducing, refining, or even replacing testing on animals. To meet these requirements, experimental toxicologists and risk assessors are adopting quantitative approaches and computer simulations to study the biological fate and effects of chemicals and drugs. In Quantitative Modeling in Toxicology leading experts outline the current state of knowledge on the modeling of dose, tissue interactions and tissue responses. Each chapter describes the mathematical foundation, parameter estimation, challenges and perspectives for development, along with the presentation of a modeling template. Additionally, tools and approaches for conducting uncertainty, sensitivity and variability analyses in these models are described. Topics covered include: the quantitative models of pharmacokinetics of individual chemicals and mixtures models for toxicant-target tissue interaction. models for cellular, organ, and organism responses. approaches, tools and challenges for model application and evaluation A website containing computer codes accompanies the book to help the reader reconstruct the models described and discussed in the various chapters. Quantitative Modeling in Toxicology serves as an essential reference source and tool box for risk assessors and researchers and students in toxicology, public health, pharmacology, and human toxicology interested in developing quantitative models for a better understanding of dose-response relationships.

Basic Pharmacokinetics and Pharmacodynamics

Basic Pharmacokinetics and Pharmacodynamics
An Integrated Textbook and Computer Simulations

by Sara E. Rosenbaum

  • Publisher : John Wiley & Sons
  • Release : 2016-11-28
  • Pages : 576
  • ISBN : 1119143187
  • Language : En, Es, Fr & De
GET BOOK

Updated with new chapters and topics, this book provides a comprehensive description of all essential topics in contemporary pharmacokinetics and pharmacodynamics. It also features interactive computer simulations for students to experiment and observe PK/PD models in action. • Presents the essentials of pharmacokinetics and pharmacodynamics in a clear and progressive manner • Helps students better appreciate important concepts and gain a greater understanding of the mechanism of action of drugs by reinforcing practical applications in both the book and the computer modules • Features interactive computer simulations, available online through a companion website at: https://web.uri.edu/pharmacy/research/rosenbaum/sims/ • Adds new chapters on physiologically based pharmacokinetic models, predicting drug-drug interactions, and pharmacogenetics while also strengthening original chapters to better prepare students for more advanced applications • Reviews of the 1st edition: “This is an ideal textbook for those starting out ... and also for use as a reference book ...." (International Society for the Study of Xenobiotics) and “I could recommend Rosenbaum’s book for pharmacology students because it is written from a perspective of drug action . . . Overall, this is a well-written introduction to PK/PD .... “ (British Toxicology Society Newsletter)

Pharmacokinetic-Pharmacodynamic Modeling and Simulation

Pharmacokinetic-Pharmacodynamic Modeling and Simulation
A Book

by Peter L. Bonate

  • Publisher : Springer Science & Business Media
  • Release : 2006-05-14
  • Pages : 388
  • ISBN : 0387271996
  • Language : En, Es, Fr & De
GET BOOK

A natural hierarchy exists in pharmacokinetic-pharmacodynamic modeling culminating in population pharmacokinetic models, which are a specific type of nonlinear mixed effects model. The purpose of this book is to present through theory and example how to develop pharmacokinetic models, both at an individual and population level. In order to do so, however, one must first understand linear models and then build to nonlinear models followed by linear mixed effects models and then ultimately nonlinear mixed effects models. This book develops in that manner – each chapter builds upon previous chapters by first presenting the theory and then illustrating the theory using published data sets and actual data sets that were used in the development of new chemical entities collected by the author during his years in industry. A key feature of the book is the process of modeling. Most books and manuscripts often present the final model never showing how the model evolved. In this book all examples are presented in an evolutionary manner.

Drug Transporters

Drug Transporters
A Book

by Martin F. Fromm,Richard B. Kim

  • Publisher : Springer Science & Business Media
  • Release : 2010-11-19
  • Pages : 454
  • ISBN : 9783642145414
  • Language : En, Es, Fr & De
GET BOOK

It is increasingly recognized that various transporter proteins are expressed throughout the body and determine absorption, tissue distribution, biliary and renal elimination of endogenous compounds and drugs and drug effects. This book will give an overview on the transporter families which are most important for drug therapy. Most chapters will focus on one transporter family highlighting tissue expression, substrates, inhibitors, knock-out mouse models and clinical studies.

Human Biomonitoring for Environmental Chemicals

Human Biomonitoring for Environmental Chemicals
A Book

by National Research Council,Division on Earth and Life Studies,Board on Environmental Studies and Toxicology,Committee on Human Biomonitoring for Environmental Toxicants

  • Publisher : National Academies Press
  • Release : 2006-10-30
  • Pages : 316
  • ISBN : 9780309133906
  • Language : En, Es, Fr & De
GET BOOK

Biomonitoring—a method for measuring amounts of toxic chemicals in human tissues—is a valuable tool for studying potentially harmful environmental chemicals. Biomonitoring data have been used to confirm exposures to chemicals and validate public health policies. For example, population biomonitoring data showing high blood lead concentrations resulted in the U.S. Environmental Protection Agency's (EPA's) regulatory reduction of lead in gasoline; biomonitoring data confirmed a resultant drop in blood lead concentrations. Despite recent advances, the science needed to understand the implications of the biomonitoring data for human health is still in its nascent stages. Use of the data also raises communication and ethical challenges. In response to a congressional request, EPA asked the National Research Council to address those challenges in an independent study. Human Biomonitoring for Environmental Chemicals provides a framework for improving the use of biomonitoring data including developing and using biomarkers (measures of exposure), research to improve the interpretation of data, ways to communicate findings to the public, and a review of ethical issues.

Iodotrifluoromethane

Iodotrifluoromethane
Toxicity Review

by National Research Council,Division on Earth and Life Studies,Board on Environmental Studies and Toxicology,Committee on Toxicology,Subcommittee on Iodotrifluoromethane

  • Publisher : National Academies Press
  • Release : 2004-12-23
  • Pages : 112
  • ISBN : 0309093074
  • Language : En, Es, Fr & De
GET BOOK

The U.S. military is considering using a compound called iodotrifluoromethane (CF3I) for fire suppression to replace previously-used compounds (halons) that are being phased out because they deplete the ozone layer. This report reviews available toxicological data on CF3I and evaluates the scientific basis of the U.S. Army's proposed exposure limit of 2,000 parts per million (ppm). The report recommends that CF3I be used for fire suppression in normally unoccupied spaces because of its potential to cause cardiac sensitization in test animals. The report also recommends that further genotoxicity testing be conducted (testing for changes in genetic material), and that CF3I be assessed for its potential to cause cancer. Should the Army decide to use CF3I, information should be collected and evaluated on how much of the chemical or any of its degradation products might be released and how often.

Transporters in Drug Development

Transporters in Drug Development
Discovery, Optimization, Clinical Study and Regulation

by Yuichi Sugiyama,Bente Steffansen

  • Publisher : Springer Science & Business Media
  • Release : 2013-09-16
  • Pages : 317
  • ISBN : 1461482291
  • Language : En, Es, Fr & De
GET BOOK

Transporters in Drug Development examines how membrane transporters can be dealt with in academic–industrial drug discovery and pharmaceutical development as well as from a regulatory perspective. The book describes methods and examples of in vitro characterization of single transporters in the intestines, liver and kidneys as well as characterization of substrate overlap between various transporters. Furthermore, probes and biomarkers are suggested for studies of the transporters’ impact on the pharmacokinetics of drug substrates/candidates interacting on transporters. The challenges of translating in vitro observed interaction of transporters into in vivo relevance are explored, and the book highlights perspectives of applying targeted proteomics and mechanistic modeling in this process.

Pharmaceutical Nanotechnology

Pharmaceutical Nanotechnology
Innovation and Production, 2 Volumes

by Jean Cornier

  • Publisher : John Wiley & Sons
  • Release : 2017-02-06
  • Pages : 775
  • ISBN : 3527340548
  • Language : En, Es, Fr & De
GET BOOK

With its focus on concrete methods and recent advances in applying nanotechnology to develop new drug therapies and medical diagnostics, this book provides an overall picture of the field, from the fundamentals of nanopharmacy with the characterisation and manufacturing methods to the role of nanoparticles and substances. Actual examples of utilization include drug development issues, translation to the clinic, market prospects, and industrial commercialization aspects. The applications described are taken from cancer treatment as well as other major therapeutic areas, such as infectious diseases and dermatology. An in-depth discussion on safety, regulatory, and societal aspects rounds off the book. Written by a top team of editors and authors composed of the leading experts in Europe and the USA who have pioneered the field of nanopharmacy!

Arsenic

Arsenic
Exposure Sources, Health Risks, and Mechanisms of Toxicity

by J. Christopher States

  • Publisher : John Wiley & Sons
  • Release : 2015-11-02
  • Pages : 576
  • ISBN : 111851114X
  • Language : En, Es, Fr & De
GET BOOK

"This book acts as a compendium of up-to-date knowledge on arsenic as a toxicant, its exposure sources, health risks, and mechanisms"--